Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANVS Annovis Bio	$2.37 -2.5%	$2.61	$1.11 ▼ $10.54	$46.19M	1.51	447,998 shs	89,267 shs
COEP Coeptis Therapeutics	$13.35 +1.0%	$10.35	$2.31 ▼ $14.70	$64.35M	-0.59	81,610 shs	15,979 shs
GELS Gelteq	$1.31 +2.3%	$1.67	$0.77 ▼ $5.50	$12.37M	N/A	1.19 million shs	12,088 shs
IPSC Century Therapeutics	$0.52 +2.0%	$0.57	$0.34 ▼ $1.86	$44.84M	1.78	726,779 shs	481,017 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANVS Annovis Bio	+8.93%	-6.12%	-16.30%	+0.83%	-74.72%
COEP Coeptis Therapeutics	-3.22%	-2.65%	+13.59%	+45.81%	+218.16%
GELS Gelteq	-3.76%	0.00%	-32.98%	-23.35%	+127,999,900.00%
IPSC Century Therapeutics	-0.49%	-7.51%	-18.69%	-9.16%	-74.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANVS Annovis Bio	2.3575 of 5 stars	3.3	3.0	0.0	0.0	1.9	1.7	0.6
COEP Coeptis Therapeutics	0.7738 of 5 stars	0.0	3.0	0.0	0.0	3.3	1.7	0.0
GELS Gelteq	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IPSC Century Therapeutics	3.0183 of 5 stars	3.5	4.0	0.0	0.0	2.5	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANVS Annovis Bio	2.60	Moderate Buy	$18.00	659.49% Upside
COEP Coeptis Therapeutics	0.00	N/A	N/A	N/A
GELS Gelteq	0.00	N/A	N/A	N/A
IPSC Century Therapeutics	3.00	Buy	$3.75	622.54% Upside

Current Analyst Ratings Breakdown

Latest GELS, COEP, IPSC, and ANVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/8/2025	ANVS Annovis Bio	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/9/2025	ANVS Annovis Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $12.00

(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANVS Annovis Bio	N/A	N/A	N/A	N/A	$0.94 per share	N/A
COEP Coeptis Therapeutics	$263.56K	244.06	N/A	N/A	$1.47 per share	9.08
GELS Gelteq	$100K	123.66	N/A	N/A	$1.30 per share	1.01
IPSC Century Therapeutics	$6.59M	6.80	N/A	N/A	$2.43 per share	0.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANVS Annovis Bio	-$24.59M	-$2.04	N/A	N/A	N/A	N/A	-206.01%	-158.26%	11/14/2025 (Estimated)
COEP Coeptis Therapeutics	-$10.88M	-$5.80	N/A	∞	N/A	N/A	-201.73%	-108.46%	N/A
GELS Gelteq	-$2.33M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
IPSC Century Therapeutics	-$126.57M	-$0.29	N/A	N/A	N/A	-19.10%	-11.53%	-6.94%	11/4/2025 (Estimated)

Latest GELS, COEP, IPSC, and ANVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	COEP Coeptis Therapeutics	N/A	-$1.17	N/A	-$1.17	N/A	$0.20 million
8/14/2025	Q2 2025	IPSC Century Therapeutics	-$0.38	-$0.38	N/A	-$0.38	$0.03 million	N/A
8/12/2025	Q2 2025	ANVS Annovis Bio	-$0.36	-$0.32	+$0.04	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
COEP Coeptis Therapeutics	N/A	N/A	N/A	N/A	N/A
GELS Gelteq	N/A	N/A	N/A	N/A	N/A
IPSC Century Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANVS Annovis Bio	N/A	7.65	7.65
COEP Coeptis Therapeutics	0.02	0.83	0.83
GELS Gelteq	N/A	0.79	N/A
IPSC Century Therapeutics	N/A	10.72	10.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANVS Annovis Bio	15.83%
COEP Coeptis Therapeutics	13.88%
GELS Gelteq	N/A
IPSC Century Therapeutics	50.20%

Insider Ownership

Company	Insider Ownership
ANVS Annovis Bio	20.80%
COEP Coeptis Therapeutics	24.25%
GELS Gelteq	N/A
IPSC Century Therapeutics	5.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANVS Annovis Bio	3	19.49 million	15.43 million	Optionable
COEP Coeptis Therapeutics	2	4.82 million	3.65 million	Not Optionable
GELS Gelteq	N/A	9.44 million	N/A	N/A
IPSC Century Therapeutics	170	86.39 million	82.07 million	Optionable

GELS, COEP, IPSC, and ANVS Headlines

Recent News About These Companies

Century Therapeutics to Present at Global Investment Conference

August 23, 2025 | msn.com

HC Wainwright Analysts Raise Earnings Estimates for IPSC

August 23, 2025 | americanbankingnews.com

Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

August 22, 2025 | globenewswire.com

Century Therapeutics (NASDAQ:IPSC) Rating Lowered to Sell at Wall Street Zen

August 18, 2025 | americanbankingnews.com

Century Therapeutics, Inc.: Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

August 15, 2025 | finanznachrichten.de

Century Reports Flat Loss in Fiscal Q2

August 15, 2025 | theglobeandmail.com

Century Therapeutics Reports Q2 2025 Financials and Updates

August 14, 2025 | tipranks.com

Century Therapeutics Reports Q2 Results and Leadership Change

August 14, 2025 | msn.com

Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

August 14, 2025 | globenewswire.com

Century Therapeutics (NASDAQ:IPSC) Shares Down 8.7% - Here's Why

July 30, 2025 | marketbeat.com

All You Need to Know About Century Therapeutics (IPSC) Rating Upgrade to Strong Buy

July 21, 2025 | zacks.com

Century Therapeutics Inc. Stock Grades | IPSC | Barron's

July 16, 2025 | barrons.com

Despite Fast-paced Momentum, Century Therapeutics (IPSC) Is Still a Bargain Stock

July 15, 2025 | sharewise.comS

Despite Fast-paced Momentum, Century Therapeutics (IPSC) Is Still a Bargain Stock

July 15, 2025 | zacks.com

University City biotech Century Therapeutics is cutting 72 jobs, about half its workforce

July 11, 2025 | msn.com

Century Therapeutics to Cut 51% of Workforce

July 8, 2025 | marketwatch.com

Century Therapeutics (IPSC) Is Attractively Priced Despite Fast-paced Momentum - Nasdaq

June 27, 2025 | nasdaq.com

Century Therapeutics, Inc. (IPSC) - Yahoo Finance

June 26, 2025 | sg.finance.yahoo.com

Century Therapeutics (IPSC) Is Attractively Priced Despite Fast-paced Momentum

June 25, 2025 | zacks.com

IPSC Century Therapeutics, Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain

June 6, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GELS, COEP, IPSC, and ANVS Company Descriptions

Annovis Bio NYSE:ANVS

$2.37 -0.06 (-2.47%)

As of 03:57 PM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Coeptis Therapeutics NASDAQ:COEP

$13.34 +0.14 (+1.02%)

As of 03:57 PM Eastern

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Gelteq NASDAQ:GELS

$1.31 +0.03 (+2.34%)

As of 03:11 PM Eastern

Gelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.

Century Therapeutics NASDAQ:IPSC

$0.52 +0.01 (+2.02%)

As of 03:57 PM Eastern

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time